HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: The Company manufactures and sells apparatus, instruments, and consumables for life science research. Operations are focused on the Apparatus and Instrumentation Business segment. The Capital Equipment Business segment is reported as discontinued operations pending divestiture.

Key Financial Metrics

Note: Debt figures include $2.3 million in notes payable assumed from the Panlab acquisition and $101k in long-term debt. Revolving credit facility was $0 outstanding as of March 31, 2008.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 14.9% ($2.8 million) driven by the acquisition of Panlab ($2.4 million), increased sales at Biochrom UK ($1.9 million), and favorable foreign exchange rates ($0.4 million). This was partially offset by the absence of large one-off orders from China present in Q1 2007.
• Margin Compression: Gross margin decreased to 47.0% from 49.3%. This decline is attributed to Panlab's lower margin profile (higher mix of distributed vs. manufactured products) and $0.3 million in inventory write-downs related to restructuring.
• Operating Expenses: Total operating expenses rose 22.4% to $8.8 million. Increases were driven by R&D ($0.2 million), Sales & Marketing ($0.4 million), and G&A ($0.4 million), largely due to Panlab integration and a new shareholder rights plan. Restructuring charges of $0.6 million were recorded in Q1 2008 (none in Q1 2007).
• Discontinued Operations: Loss from discontinued operations improved to $0.5 million (net of tax) from $1.2 million in the prior year, reflecting the sale of the Genomic Solutions Division and MAIA Scientific in late 2007.
• Liquidity: Cash decreased by $5.2 million primarily due to $5.6 million in debt repayments and increased inventory levels to support new product launches.

Guidance, Outlook, and Risks

• Strategic Initiatives: Management outlined five initiatives for 2008: launch of a new Harvard Apparatus catalog, Panlab product launch in the US, a new contract with GE Healthcare, new 2-D electrophoresis products, and consolidation of business functions to reduce expenses.
• Restructuring: The Company is consolidating operations (e.g., moving Hoefer admin to Holliston, MA; consolidating Asys Hitech into Biochrom UK). Total expected costs are between $1.6 million and $1.9 million, with the majority expected in the first half of 2008.
• Divestiture Risk: The Company is pursuing the sale of the remaining Capital Equipment Business segment (Union Biometrica). The credit facility requires lender consent for this sale; failure to obtain consent could trigger a default and acceleration of debt.
• Foreign Exchange: The Company has significant exposure to the British Pound and Euro. A 10% appreciation in these currencies would increase foreign exchange losses by approximately $0.5 million.
• Capital Resources: The Company has $20.0 million available under its revolving credit facility. Management expects current cash and debt capacity to be sufficient for operations for 12 months and beyond, though additional capital may be needed for significant acquisitions.

Investor Verification Checklist

• Restructuring Execution: Verify the timeline and actual costs of the ongoing consolidation initiatives to ensure they align with the $1.6M-$1.9M estimate.
• Discontinued Operations Sale: Monitor progress on the sale of the Union Biometrica product line and confirm lender consent for the transaction to avoid credit facility default.
• Panlab Integration: Assess whether Panlab's lower gross margins stabilize or improve as the product mix shifts toward manufactured goods.
• GE Healthcare Contract: Confirm the impact of the new exclusive distribution agreement with GE Healthcare on future revenue streams for spectrophotometers.
• Inventory Levels: Review inventory turnover given the $1.2 million increase in inventory during the quarter to ensure no further write-downs are necessary.